Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159


SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.

Kuwahara Y, Wei D, Durand J, Weissman BE.

Mol Cancer Res. 2013 Mar;11(3):251-60. doi: 10.1158/1541-7786.MCR-12-0390. Epub 2013 Jan 30.


Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism.

Kuwahara Y, Charboneau A, Knudsen ES, Weissman BE.

Cancer Res. 2010 Mar 1;70(5):1854-65. doi: 10.1158/0008-5472.CAN-09-1922. Epub 2010 Feb 23.


SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.

Wei D, Goldfarb D, Song S, Cannon C, Yan F, Sakellariou-Thompson D, Emanuele M, Major MB, Weissman BE, Kuwahara Y.

Mol Cancer Res. 2014 Nov;12(11):1574-85. doi: 10.1158/1541-7786.MCR-14-0005. Epub 2014 Jul 9.


Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.

Lee S, Cimica V, Ramachandra N, Zagzag D, Kalpana GV.

Cancer Res. 2011 May 1;71(9):3225-35. doi: 10.1158/0008-5472.CAN-10-2167. Epub 2011 Apr 26.


The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.

Caramel J, Medjkane S, Quignon F, Delattre O.

Oncogene. 2008 Mar 27;27(14):2035-44. Epub 2007 Oct 8.


SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus.

Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP.

Mol Cell Biol. 2008 May;28(10):3457-64. doi: 10.1128/MCB.02019-07. Epub 2008 Mar 10.


Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.

Darr J, Klochendler A, Isaac S, Geiger T, Eden A.

Mol Cancer. 2015 Sep 15;14:167. doi: 10.1186/s12943-015-0439-5. Erratum in: Mol Cancer. 2016;15:14. Geiger, Tami [Corrected to Geiger, Tamar].


P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells.

Oruetxebarria I, Venturini F, Kekarainen T, Houweling A, Zuijderduijn LM, Mohd-Sarip A, Vries RG, Hoeben RC, Verrijzer CP.

J Biol Chem. 2004 Jan 30;279(5):3807-16. Epub 2003 Nov 6.


Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.

Wöhrle S, Weiss A, Ito M, Kauffmann A, Murakami M, Jagani Z, Thuery A, Bauer-Probst B, Reimann F, Stamm C, Pornon A, Romanet V, Guagnano V, Brümmendorf T, Sellers WR, Hofmann F, Roberts CW, Graus Porta D.

PLoS One. 2013 Oct 30;8(10):e77652. doi: 10.1371/journal.pone.0077652. eCollection 2013.


Integrase interactor 1 in health and disease.

Das S.

Curr Protein Pept Sci. 2015;16(6):478-90. Review.


Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors.

McKenna ES, Tamayo P, Cho YJ, Tillman EJ, Mora-Blanco EL, Sansam CG, Koellhoffer EC, Pomeroy SL, Roberts CW.

Cell Cycle. 2012 May 15;11(10):1956-65. doi: 10.4161/cc.20280. Epub 2012 May 15.


Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors.

Uno K, Takita J, Yokomori K, Tanaka Y, Ohta S, Shimada H, Gilles FH, Sugita K, Abe S, Sako M, Hashizume K, Hayashi Y.

Genes Chromosomes Cancer. 2002 May;34(1):33-41.


Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.

Kim KH, Roberts CW.

Cancer Genet. 2014 Sep;207(9):365-72. doi: 10.1016/j.cancergen.2014.04.004. Epub 2014 Apr 13. Review.


Human SNF5/INI1, a component of the human SWI/SNF chromatin remodeling complex, promotes nucleotide excision repair by influencing ATM recruitment and downstream H2AX phosphorylation.

Ray A, Mir SN, Wani G, Zhao Q, Battu A, Zhu Q, Wang QE, Wani AA.

Mol Cell Biol. 2009 Dec;29(23):6206-19. doi: 10.1128/MCB.00503-09. Epub 2009 Oct 5.


RhoA-dependent regulation of cell migration by the tumor suppressor hSNF5/INI1.

Caramel J, Quignon F, Delattre O.

Cancer Res. 2008 Aug 1;68(15):6154-61. doi: 10.1158/0008-5472.CAN-08-0115.


Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.

Darr J, Klochendler A, Isaac S, Eden A.

Oncogene. 2014 Jun 5;33(23):3024-32. doi: 10.1038/onc.2013.261. Epub 2013 Jul 15.


Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression.

Hasselblatt M, Gesk S, Oyen F, Rossi S, Viscardi E, Giangaspero F, Giannini C, Judkins AR, Frühwald MC, Obser T, Schneppenheim R, Siebert R, Paulus W.

Am J Surg Pathol. 2011 Jun;35(6):933-5. doi: 10.1097/PAS.0b013e3182196a39.


Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors.

DeCristofaro MF, Betz BL, Wang W, Weissman BE.

Oncogene. 1999 Dec 9;18(52):7559-65.


Cancer-associated mutations in chromatin remodeler hSNF5 promote chromosomal instability by compromising the mitotic checkpoint.

Vries RG, Bezrookove V, Zuijderduijn LM, Kia SK, Houweling A, Oruetxebarria I, Raap AK, Verrijzer CP.

Genes Dev. 2005 Mar 15;19(6):665-70.

Supplemental Content

Support Center